Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti‐TNF alpha: 5‐year follow‐up study
Alimentary Pharmacology & Therapeutics2015Vol. 42(7), pp. 880–888
Citations Over TimeTop 10% of 2015 papers
Daniela Pugliese, Luisa Guidi, Pietro Manuel Ferraro, Manuela Marzo, Carla Felice, Leonardo Celleno, Rosario Landi, G. Andrisani, Fabrizio Pizzolante, I. De Vitis, Alfredo Papa, Gian Lodovico Rapaccini, Alessandro Armuzzi
Abstract
Paradoxical psoriasis is a relevant side effect of anti-TNF alpha therapy, with an incidence rate of five per 100 person-years. Smoking is confirmed as the main risk factor for developing lesions. The combination therapy with anti-TNF alpha plus immunosuppressants is associated with a reduced risk of paradoxical psoriasis.
Related Papers
- → THU0211 Six months after treatment discontinuation tnf is still in complex with adalimumab(2018)1 cited
- → The Effect of Adalimumab on Refractory Uveitis(2020)1 cited
- → FRI0165 A prediction tool for drug monitoring of adalimumab in rheumatoid arthritis.(2013)
- 강직성 척추염 환자에서 Adalimumab 치료 후 관찰된 천장관절염의 회복 1예 Running title: 강직성 척추염에서 Adalimumab 치료와 천장관절염의 회복(2012)
- → Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial(2023)